Evidence map›Paper›PMID 39885500›Full record

ArticleBMC surgery2025

Allograft tolerance after adult living donor liver transplantation: a case-control study.

Mohamed S Habl, Moataz Maher Emara, Reham A Zayed, Ahmed M Sultan, Ahmed Elsabagh, Ahmed Marwan Elsaid, Ehab E Abdel-Khalek, Mohamed M El-Saadany, Mohamed Abdel Wahab, Ahmed Shehta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohamed S Habl *Department of Hepatology and Gastroenterology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Moataz Maher Emara *Department of Anesthesiology and Intensive Care and Pain Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Reham A ZayedDepartment of Hepatology and Gastroenterology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ahmed M SultanDepartment of Anesthesiology and Intensive Care and Pain Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ahmed ElsabaghDepartment of Hepatology and Gastroenterology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ahmed Marwan ElsaidDepartment of Hepatology and Gastroenterology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ehab E Abdel-KhalekDepartment of Hepatology and Gastroenterology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed M El-SaadanyDepartment of Hepatology and Gastroenterology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed Abdel WahabDepartment of Anesthesiology and Intensive Care and Pain Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ahmed ShehtaDepartment of Anesthesiology and Intensive Care and Pain Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt. ahmedshehta@mans.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate the incidence and potential predictors of immune tolerance among adult living donor liver transplant (LDLT) recipients.

methodsThis case-control study included adult recipients who underwent LDLT between May 2004 and January 2018, with at least a 5-year follow-up after LDLT. We divided the study recipients into two groups: Group 1 (Tolerance Group) included recipients who achieved operational or prope tolerance for at least one year; Group 2 (Control Group) included recipients who did not achieve tolerance. We used logistic regression analysis to study the potential predictors of tolerance after LDLT.

resultsWe included 368 recipients, 275 (74.7%) in Group 1 and 93 (25.3%) in Group 2. Operational tolerance occurred in 13/275 (4.7%) recipients and prope tolerance in 262/275 (95.3%) recipients. Age was significantly higher in Group 1. The median time for tolerance among the study recipients was 60 months (36-168). During follow-up, Group 1 showed lower serum levels of bilirubin, liver enzymes, alkaline phosphatase, and gamma-glutamyl transferase. Group 1 had a lower incidence of acute cellular rejection (ACR), recurrent viral hepatitis, and biliary complications. Logistic regression identified preoperative MELD, indication for LDLT, ACR, recurrent viral hepatitis, and biliary complications as significant predictors for allograft tolerance after LDLT.

conclusionAllograft tolerance occurred in 74.7% of this cohort. We suggest that the MELD score, indication for LT, ACR, recurrent viral hepatitis, and biliary complications are predictors of allograft tolerance after LDLT.

Indexed as

Liver TransplantationLiving DonorsTransplantation ToleranceAdultCase-Control StudiesFemaleFollow-Up StudiesGraft RejectionHumansMaleMiddle AgedRetrospective StudiesAllograft toleranceGraft rejectionImmunosuppressionLiving-donor liver transplantation

Identifiers

PMID39885500
PMCPMC11783700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.